Saturday 17 October 2026 Export TMCI’s income statement to Excel — free account

Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024. In the quarter to June 2026, revenue fell 4.24%, EPS grew 14.3%, free cash flow grew 11.7% and total debt rose 4.84%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.87 0.25 −6.07%

Follow TMCI

Alert me

Market cap: $267.9M
P/E: 0.0×
Fwd P/E: −3.9×
Dividend yield: —
F-score: 2/9
Altman Z: −0.11
Beneish M: −3.51
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.45

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	2	3	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 26.72%

Capital & Financial Ratios $m

Market Cap 267.94

Revenue 205.31

Net Income (59.52)

Free Cash Flow (25.05)

Net Debt 10.42

Current Ratio 2.90

Debt/Equity 0.83

P/E ratio 0.00

Fwd P/E (3.90)

P/S ratio 1.23

P/B ratio 3.72

Past 5Y EPS Growth —

This Y EPS Growth 8.60%

Next Y EPS Growth 8.94%

Next Y revenue growth (2.44%)

Next 5Y EPS Growth 9.18%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.74%

10-year low 10-year high

P/B against its own 10 years 23.07%

10-year low 10-year high

EV/Sales against its own 10 years 11.32%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	123	76	48	46
Receivables	38	41	42	29
Inventory	29	39	36	40
Other	—	—	—	—
	198	161	132	120

	2023	2024	2025	Q'26
Payables	12	11	7	16
ST’ Debt	—	—	—	—
Other	4	1	2	4
	45	35	31	41

Compound Annual Growth %

	10y	5y	3y
Sales	—	29.96%	14.46%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	157.19%	13.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	47	45	—	—	—
’25	53	47	50	63	213
’24	51	44	45	69	209
’23	42	42	41	62	187
’22	29	30	33	50	142
’21	19	21	22	33	94
’20	11	8	14	24	57

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	7	(5)	—	—	—
’25	4	(3)	(9)	(8)	(16)
’24	(7)	(14)	(12)	(4)	(37)
’23	(17)	(8)	(10)	1	(35)
’22	(7)	(11)	(7)	(5)	(31)
’21	0	(4)	(9)	(4)	(17)
’20	(1)	(2)	(4)	2	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	4	(7)	—	—	—
’25	1	(8)	(12)	(10)	(29)
’24	(11)	(16)	(15)	(7)	(49)
’23	(19)	(13)	(13)	(2)	(46)
’22	(9)	(16)	(13)	(8)	(45)
’21	(1)	(4)	(10)	(5)	(20)
’20	(2)	(2)	(4)	2	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.28)	(0.24)	—	—	—
’25	(0.25)	(0.28)	(0.26)	(0.15)	(0.93)
’24	(0.30)	(0.34)	(0.25)	(0.01)	(0.90)
’23	(0.23)	(0.20)	(0.28)	(0.10)	(0.81)
’22	(0.16)	(0.31)	(0.22)	(0.08)	(0.77)
’21	(0.07)	(0.10)	(0.12)	(0.12)	(0.43)
’20	(0.04)	(0.05)	(0.07)	0.07	(0.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	15.00	12.48	5.27	3.92	2.36	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	37.17	25.02	27.97	15.98	10.79
People
People	Employees	—	—	—	—	133	248	423	516	477	450
	Revenue/emp, $m	—	—	—	0.00	0.43	0.38	0.34	0.36	0.44	0.47
Income, $m
Income, $m	Revenue	—	—	—	39	57	94	142	187	209	213
	Gross margin, %	—	—	—	80.64	78.26	82.11	82.00	81.20	80.37	79.81
	EBT	—	—	—	(4)	(4)	(21)	(43)	(50)	(56)	(59)
	EBT margin, %	—	—	—	(10.82)	(6.39)	(21.77)	(30.19)	(26.47)	(26.63)	(27.74)
	Net income	—	0	—	(4)	(4)	(21)	(43)	(50)	(56)	(59)
	Depreciation	—	—	—	1	1	1	2	4	8	11
Per share, $
Per share, $	Revenue	—	—	—	1.07	1.55	1.95	2.57	3.08	3.37	3.36
	Earnings	—	—	—	(0.12)	(0.10)	(0.43)	(0.77)	(0.81)	(0.90)	(0.93)
	Cash flow	—	—	—	(0.21)	(0.12)	(0.36)	(0.55)	(0.57)	(0.60)	(0.25)
	Capex	—	—	—	(0.03)	(0.03)	(0.06)	(0.27)	(0.19)	(0.19)	(0.21)
	Free cash flow	—	—	—	(0.24)	(0.15)	(0.41)	(0.82)	(0.76)	(0.78)	(0.47)
	Book value	—	—	—	0.00	0.02	1.92	1.10	2.27	1.82	1.38
	Shares, m	—	—	—	37	37	48	55	61	62	63
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	14.91	14.91	9.56	8.73	4.08	2.21	0.73
	P/B	—	—	—	0.00	0.00	9.70	20.45	5.54	4.09	1.77
	EV/Sales	—	—	—	15.14	15.14	8.77	8.54	3.72	2.11	0.77
	EV/FCF	—	—	—	(211.71)	(211.71)	(41.61)	(26.62)	(15.12)	(9.06)	(5.56)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(8)	(4)	(17)	(31)	(35)	(37)	(16)
	Capex	—	—	—	(1)	(1)	(3)	(15)	(11)	(12)	(14)
	Free cash flow	—	—	—	(9)	(6)	(20)	(45)	(46)	(49)	(29)
Balance, $m
Balance, $m	Working capital	—	—	—	21	29	120	103	153	126	101
	Total debt	—	—	—	19	31	30	53	53	53	56
	Net debt	—	—	—	7	13	(76)	(29)	(70)	(22)	7
	Shareholders’ equity	—	—	—	—	1	93	61	138	113	87
Returns, %
Returns, %	ROA	—	—	—	0.00	(20.61)	(22.72)	(28.56)	(24.10)	(23.77)	(28.95)
	ROIC	—	—	—	(31.19)	3.84	(61.50)	(68.08)	(47.44)	(38.45)	(35.80)
	ROE	—	—	—	82.21	72.20	(48.30)	(55.75)	(49.91)	(44.45)	(58.94)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
Median of peers	$262.8M	20.0×	—	+2.16%	—	−33.22%	70.04%	(110.21%)

All 149 Medical Devices stocks →

Treace Medical Concepts, Inc. (TMCI) key facts

Concern: Treace Medical Concepts, Inc. reported a net loss of $59.0 million, or a loss of $0.93 per share, for fiscal 2025.
Strength: Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024.
Treace Medical Concepts, Inc. (TMCI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TMCI traded at $3.87, a market capitalization of $267.9 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.2× sales.
Return on equity was −58.9% and debt-to-equity 0.83.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −0.11 (distress zone) for fiscal 2025.